Amanote Research

Amanote Research

    RegisterSign In

Überlebensvorteil Mit Ipilimumab

Best Practice Onkologie - Germany
doi 10.1007/bf03359705
Full Text
Open PDF
Abstract

Available in full text

Categories
Oncology
Date

August 1, 2010

Authors

Unknown

Publisher

Springer Science and Business Media LLC


Related search

NSCLC: Atezolizumab Mit Überlebensvorteil Unabhängig Vom PD-L1-Status

Pneumologie
MedicinePulmonaryRespiratory Medicine
2017English

Überlebensvorteil Durch Erlotinib

Info Onkologie
2010English

Ipilimumab

Drugs in R and D
Pharmacology
2010English

Ipilimumab-Induced Hypophysitis: MR Findings

Global Imaging Insights
2017English

Infliximab for IPILIMUMAB-Related Colitis--Letter

Clinical Cancer Research
Cancer ResearchOncology
2015English

Phase I Trial: SABR and Ipilimumab—Letter

Clinical Cancer Research
Cancer ResearchOncology
2017English

GM-CSF/Ipilimumab Combination Extends Melanoma Survival

Cancer Discovery
Oncology
2013English

Adjuvant Ipilimumab in High-Risk Uveal Melanoma

Cancers
Cancer ResearchOncology
2019English

Autoimmune Inflammatory Myopathy After Treatment With Ipilimumab

Canadian Journal of Neurological Sciences
MedicineNeurology
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy